Resources

Webinars

Post-Grant for Practitioners: A bi-monthly series of webinars focusing on developments in post-grant proceedings and related practice tips.

Fish & Richardson is the most active firm in post-grant proceedings at the PTAB. In 2012, we kicked-off a webinar series designed to share practice tips, nuances, observations, and strategy. Recordings for previous webinars in this series are included below, with the most recent appearing first.

WEBINAR ARCHIVES:   2019  |  2018  |  2017  |  2016  |  2015  |  2014  |  2013  |  2012

2020 Webinar Series

July 10, 2020

Post-Grant for Practitioners Webinar | Just the Facts – A Mid-Year Review

In this Fish webinar, Fish attorneys John DragsethLauren Degnan, and Rob Courtney will provide a mid-year review of current developments in post-grant practice.

Topics to be covered include:

  • Thryv v. Click-to-Call and other issues concerning the appealability of institution decisions
  • GE v. United Technologies and other issues concerning petitioner standing to appeal IPR decisions
  • A practical update of Arthrex  – Where are we? What’s next?
  • An update on issues concerning IPR-related estoppels

Register Today!

Thursday, August 6, 2020

1:30 – 2:30 pm EDT

To register, please click here.

Fish & Richardson will apply for 1.0 hour of CLE credit.

If you have any questions, please contact Jane Lundberg.

Speakers:
Rob Courtney
Lauren Degnan
John Dragseth



January 16, 2020

Biosimilars – 2019 Year in Review

Life sciences attorneys John Adkisson, Tasha Francis, and Jenny Shmuel provide a review of current legal and regulatory developments that have had an impact on the U.S. biosimilar industry. Topics discussed during this webinar include:

  • 2019 biosimilar approvals, launches, and anticipated launches
  • Summary of FDA guidance in 2019
  • Updates regarding pending court cases and appellate decisions
  • 2019 IPR trends
  • What to look forward to in 2020!

Download a copy of the slides here

Speakers:
John Adkisson
Tasha Francis, Ph.D.
Jenny Schmuel, Ph.D.



January 8, 2020

Post-Grant for Practitioners: 2019 Year in Review

From the establishment of the PTAB Precedential Opinion Panel to an updated Trial Practice Guide to a decision throwing the constitutionality of PTAB appointments into question, 2019 was a busy year in post-grant practice. Join Fish Principals and Post-Grant Practice Co-Chairs Dorothy Whelan and Karl Renner as they take a closer look at the most significant developments in post-grant jurisprudence from 2019 and their impact on practitioners. Dorothy and Karl discuss:

  • PTAB statistics and trends
  • The PTAB’s Precedential Opinion Panel and some of the decisions it designated this year
  • Important Federal Circuit and Supreme Court decisions, including:
    • Celgene Corp. v. Peter
    • Arthrex, Inc. v. Smith & Nephew, Inc.
    • Return Mail, Inc. v. United States Postal Service
  • What to watch for in 2020

Download a copy of the slides here.

Speakers:
Karl Renner
Dorothy Whelan



Fill out the form below to receive our monthly newsletter and updates on your selected areas of interest. You can unsubscribe at any time by clicking the unsubscribe link at the bottom of the email.

  • Fish & Richardson P.C. is committed to protecting and respecting your privacy, and we’ll only use your personal information to administer your account and to provide the services you requested from us. From time to time, we would like to contact you about our services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick below.
  • In order to provide you the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please tick the checkbox below.
  • You can unsubscribe from these communications at any time. This can be done by clicking the unsubscribe link at the bottom of marketing emails you receive from us, or by emailing info@fr.com stating that you would like to be unsubscribed.
  • This field is for validation purposes and should be left unchanged.